International Stem Cell CORP
International Stem Cell CORP (ISCO): 9 pipeline candidates · ~4 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.2 months
D/E -1.20 · 0% dilution
Lead: Approved
9 candidates
N/A
N/A
A transparent, data-derived signal for International Stem Cell CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4M
Cash
$933K
Quarterly Burn
$1.3M
Runway
4.2 mo
Revenue
$2.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| active anthrax detecttm plus rapid test | — |
| biofreedom drug coated coronary stent system | — |
| finevision hp trifocal iols | Approved |
| gonodecten | Approved |
| herceptest | Approved |
| isc-hpnsc | Phase 1 |
| lifespan 100 tcpco2 monitor | Approved |
| q 103 needle management system | Approved |
| sonolith 3000 lithotripter | Approved |
Frequently asked questions
How many drug candidates are in International Stem Cell CORP's pipeline?
International Stem Cell CORP (ISCO) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is International Stem Cell CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, International Stem Cell CORP has approximately 4.2 months of cash runway.
What is International Stem Cell CORP's market capitalization?
International Stem Cell CORP's market capitalization is approximately $1.4M.
Who is the CEO of International Stem Cell CORP?
Dr. Andrey Semechkin Ph.D. is the chief executive officer of International Stem Cell CORP (ISCO).
Get the full picture on International Stem Cell CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.